Frost & Sullivan Presents Sensus Healthcare with Prestigious New Product Innovation Leadership Award for Non-Melanoma Skin Cancer Therapy
March 21st, 2014 6:53 pm | Press Release
March 21, 2014
Boca Raton, Florida
Frost & Sullivan has recognized Sensus Healthcare with the
2014 North American award for New Product Innovation Leadership. Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value added features/benefits of the product and the increased ROI it offers customers, which in turn increases customer acquisition and overall market penetration potential.
“We are proud to accept this award on behalf of our company, our customers and the thousands of patients who have experienced marvelous outcomes from SRT treatments,” stated Joe Sardano, President/ CEO of Sensus Healthcare.
Sensus uses low-energy superficial radiotherapy (SRT) in its two products, the SRT-100™ and the SRT-100 Vision™, to effectively treat non-melanoma skin cancers and achieve a 95%+ cure rate. SRT is a proven non-invasive alternative to surgery for patients with wound closure and co-morbidity concerns, such as diabetes, cardiac disease, as well as the elderly. There is no skin removal or bleeding, sutures, scarring, pain, or loss of sensation.
The next-generation SRT-100 Vision™ integrates high-resolution ultrasound imaging and laser positioning capabilities to help with the accurate localization, characterization, and topology of lesions. This in turn will ensure optimal energy dosage, treatment fractionation and depth of beam penetration.
“Receiving the Frost & Sullivan New Product Innovation Leadership Award for Non-Melanoma Skin Cancer Therapy is a wonderful validation for a very useful and needed technology,” stated Kal Fishman, CTO of Sensus Healthcare.
The SRT-100™ and SRT-100 Vision™ recently received FDA 510(k) clearance for also treating keloids – chronic non-malignant tumors, associated with ethnic skin types, that form at the site of skin trauma, such as piercings, accidents, or general surgery including: OB/GYN, orthopedics, cardiology, plastic surgery and cutaneous surgery. Keloids recur in 90% of cases when surgery alone is used to remove them. The recurrence of keloids is reduced to 10% (0% in many cases) when a protocol of SRT and surgery is followed – resulting in a 90% to 100% cure rate. It is estimated there are more than 18 million people who are affected with keloids in the U.S.
Sensus Healthcare will be demonstrating their complete lineup of innovative skin therapy solutions in their exhibit (# 1745) at the 72nd American Academy of Dermatology (AAD) Annual Meeting being held in Denver, Colorado, March 21-25. This is the world’s largest dermatology meeting, with more than 8,300 dermatologists registered to learn the latest on the diagnosis, prevention and treatment of dermatologic disease from the foremost experts.
For more information please contact:
About Sensus Healthcare
Sensus Healthcare LLC (Boca Raton, FL) is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.
The Benefits of SRT
Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:
- 95%+ cure rates that rival surgery
- No anesthesia, cutting, bleeding, stitching or pain
- No downtime or lifestyle restrictions
- Super cosmesis, no unsightly scarring
- No need for post-treatment reconstructive surgeries